ReviewHepatology communications2019
Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists.
Review in Hepatology communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.Digestive diseases (Basel, Switzerland) · 2021Trial
- Article
- Effect of prophylactic platelet transfusion on bleeding risk in patients with cirrhosis and thrombocytopenia undergoing ultrasound-guided liver biopsy.Ultrasonography (Seoul, Korea) · 2026Article
- Coagulation Abnormalities in Liver Cirrhosis: Diagnostic and Therapeutic Approaches.Medicina (Kaunas, Lithuania) · 2026Review
- Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre-Treatment Platelet Counts: A Retrospective Multicenter Study.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- The Safety of Endoscopic Procedures in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis.Cureus · 2024Review
- Minimum platelet count threshold before invasive procedures in cirrhosis: Evolution of the guidelines.World journal of gastrointestinal surgery · 2023Review
- Hemostasis testing in patients with liver dysfunction: Advantages and caveats.World journal of gastroenterology · 2021Review
- Review
- Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag.JHEP reports : innovation in hepatology · 2021Article
- Bleeding After Elective Interventional Endoscopic Procedures in a Large Cohort of Patients With Cirrhosis.Clinical and translational gastroenterology · 2020Article
- Pathogenesis of Thrombocytopenia in Chronic HCV Infection: A Review.Journal of clinical and translational hepatology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombocytopenia is common in patients with advanced liver disease. These patients frequently require invasive diagnostic or therapeutic procedures in the setting of thrombocytopenia. A common platelet goal before such procedures is ≥50,000/μL, but target levels vary by provider and the procedure. Platelet transfusion has disadvantages, including safety and cost. No other short-term options for ameliorating thrombocytopenia before procedures were available until the thrombopoietin receptor agonists were recently approved. Avatrombopag and lusutrombopag can be used in certain patients with thrombocytopenia due to advanced liver disease undergoing elective invasive procedures; these new agents are highly effective in carefully selected patients, and real world data of safety and efficacy are awaited.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.